十二指肠溃疡治疗中新三联疗法的优势研究

The Advantage of New Triple Therapy in the Duodenal Ulcer

目的:对新三联疗法和传统三联疗法在十二指肠溃疡治疗中的疗效及安全性进行研究,证实新三联疗法的临床优势。方法:以本院2010年9月-2012年9月治疗的128例十二指肠溃疡患者为研究对象,将其随机分为对照组和观察组各64例。对照组采用埃索美拉唑镁肠溶片、克拉霉素联合阿莫西林的传统三联疗法进行治疗;观察组采用埃索美拉唑镁肠溶片、莫西沙星联合阿莫西林的新三联疗法进行治疗。连续治疗两周后,比较两组Hp根除率、有效率、不良反应发生率。结果:观察组Hp根除率为92.2%,有效率为93.8%,均高于对照组的85.9%Hp根除率和84.4%的有效率,差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:在十二指肠溃疡的治疗中,新三联疗法临床疗效及安全性均较传统的三联疗法有明显优势,适于临床推广使用。

Objective： To research efficacy and safety of the new triple therapy and the traditional three therapies in the treatment of duodenal ulcer , and confirm the clinical advantages of the new triple therapy. Method： Selected 128 cases of duodenal ulcer patients in our hospital from September 2010 to September 2012 as objects, and they were randomly divided into two groups （ each group of 64 cases ） .The control group was treated with esomeprazole magnesium enteric-coated tablets, clarithromycin amoxicillin combined traditional triple therapy for treatment.The observation group was treated with esomeprazole magnesium enteric-coated tablets, moxifloxacin new joint amoxicillin triple therapy for treatment. After two weeks of continuous treatment, take the statistical analysis on the data of Hp eradication rate , effective rate , incidence of adverse reactions and so on. Result： In the Observation group, Hp eradication rate was 92.2% , the effective rate was 93.8% and they were higher than that of the control group （ Hp eradication rate was 85.9% and the effective rate was 84.4% ） .There was significant difference between the two group （ P〈0.05 ） .In the comparison of incidence of adverse reactions and so on, the dates of the observation group were better than the control group, and there was significant difference between the two group （ P〈0.05 ） . Conclusion： In the treatment of duodenal ulcer, the new triple therapy is better than the traditional three therapies in clinical efficacy and safety , and it is worthy of clinical popularized